Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sachica Cheris"'
Autor:
Wen-Chi Foo, Tian Zhang, Jason Zhu, Landon C. Brown, Daniel J. George, Yuan Wu, Z. Su, Xin Liu, Matthew Labriola, Andrew J. Armstrong, Rajan T. Gupta, Kathryn Perkinson, Shannon J. McCall, Michael R. Harrison, Sachica Cheris, Jiaoti Huang
Publikováno v:
Clinical Genitourinary Cancer. 18:509-513
Background Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, conco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d55a30879ec2068ec5a609f2324cfd4
https://doi.org/10.1016/j.clgc.2020.03.020
https://doi.org/10.1016/j.clgc.2020.03.020
Autor:
Daniel J. George, Jason Zhu, Tian Zhang, Yuan Wu, Chester Kao, Daniele Marin, Matthew D Tucker, Patrick Healy, Matthew Labriola, Andrew J. Armstrong, Michael R. Harrison, Kedar Kirtane, Michael B. Datto, Santosh Gupta, Megan Ann McNamara, Rajan T. Gupta, Sachica Cheris
Publikováno v:
Journal of Clinical Oncology. 37:e14291-e14291
e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in responders (34%) to immune che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66bcf44b19248fee61c7aca2b4012512
https://doi.org/10.1200/jco.2019.37.15_suppl.e14291
https://doi.org/10.1200/jco.2019.37.15_suppl.e14291
Autor:
Daniel J. George, Matthew Labriola, Andrew J. Armstrong, Xin Liu, Tian Zhang, Jason Zhu, Z. Su, Sachica Cheris, Rajan T. Gupta, Jiaoti Huang, Shannon J. McCall, Kathryn Perkinson
Publikováno v:
Journal of Clinical Oncology. 37:e14259-e14259
e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivity is defined differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf62d8885a2eab44e95cc9ac50fac8c9
https://doi.org/10.1200/jco.2019.37.15_suppl.e14259
https://doi.org/10.1200/jco.2019.37.15_suppl.e14259
Autor:
Sachica Cheris, Zhongren Zhou
Publikováno v:
Journal of the American Society of Cytopathology. 5:S51
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1433c9cd8654c4f65bb77b784b12051
https://doi.org/10.1016/j.jasc.2016.07.117
https://doi.org/10.1016/j.jasc.2016.07.117